Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15946MR)

This product GTTS-WQ15946MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ15946MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14925MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ7412MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ11788MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ9184MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ3046MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ8130MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ215MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ12904MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW